The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial

Autor: Marson, Anthony, Burnside, Girvan, Appleton, Richard, Smith, Dave, Leach, John Paul, Sills, Graeme, Tudur-Smith, Catrin, Plumpton, Catrin, Hughes, Dyfrig A, Williamson, Paula, Baker, Gus A, Balabanova, Silviya, Taylor, Claire, Brown, Richard, Hindley, Dan, Howell, Stephen, Maguire, Melissa, Mohanraj, Rajiv, Smith, Philip E, Lanyon, Karen, Manford, Mark, Chitre, Manali, Parker, Alasdair, Swiderska, Nina, Pauling, James, Hughes, Adrian, Gupta, Rajat, Hanif, Sadia, Awadh, Mostafa, Ragunathan, Sharmini, Cable, Nicola, Cooper, Paul, Hindley, Daniel, Rakshi, Karl, Molloy, Sophie, Reuber, Markus, Ayonrinde, Kunle, Wilson, Martin, Saladi, Satyanarayana, Gibb, John, Funston, Lesley-Ann, Cassidy, Damhait, Boyd, Jonathan, Ratnayaka, Mal, Faza, Hani, Sadler, Martin, Al-Moasseb, Hassan, Galtrey, Clare, Wren, Damien, Olabi, Anas, Fuller, Geraint, Khan, Muhammed, Kallappa, Chetana, Chinthapalli, Ravi, Aji, Baba, Davies, Rhys, Foster, Kathryn, Hitiris, Nikolas, Hussain, Nahin, Dowson, Simon, Ellison, Julie, Sharrack, Basil, Gandhi, Vandna, Powell, Rob, Tittensor, Phil, Summers, Beatrice, Shashikiran, Sastry, Dison, Penelope J, Samarasekera, Shanika, McCorry, Doug, White, Kathleen, Nithi, Kannan, Richardson, Martin, Page, Rupert, Deekollu, David, Slaght, Sean, Warriner, Stephen, Ahmed, Mansoor, Chaudhuri, Abhijit, Chow, Gabriel, Artal, Javier, Kucinskiene, Danute, Sreenivasa, Harish, Velmurugan, Singara, Zipitis, Christos S, McLean, Brendan, Lal, Vaithianathar, Gregoriou, Angelous, Maddison, Paul, Pickersgill, Trevor, Anderson, Joseph, Lawthom, Charlotte, Whitlingum, Gabriel, Rakowicz, Wojtek, Kinton, Lucy, McLellan, Alisa, Vora, Nitish, Zuberi, Sameer, Kelso, Andrew, Hughes, Imelda, Martland, John, Emsley, Hedley, de Goede, Christian, Singh, RP, Moor, Carl-Christian, Aram, Julia, Sakthivel, Kumar, Nelapatla, Suresh, Rittey, Chris, Pinto, Ashwin, Cock, Hannah, Richardson, Anna, Houston, Erika, Cooper, Christopher, Lawson, Geoff, Massarano, Albert, Burness, Christine, Wieshmann, Udo, Dey, Indranil, Sivakumar, Puthuval, Yeung, Lap-Kong, Smith, Philip, Bentur, Hemalata, Heafield, Tom, Mathew, Anna, Smith, David, Jauhari, Praveen

Publikováno v: Mohanraj, R 2021, ' The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. ', Lancet (London, England) . https://doi.org/10.1016/s0140-6736(21)00246-4
Lancet (London, England)

Background: \ud Valproate is a first-line treatment for patients with newly diagnosed idiopathic generalised or difficult to classify epilepsy, but not for women of child-bearing potential because of teratogenicity. Levetiracetam is increasingly pres

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50b273551036e936467f978b4cb9f9f3
https://eprints.gla.ac.uk/238444/1/238444.pdf

P30 A case of varicella arthritis

Autor: Erasmus Smit, Shashikiran Sastry, Joanna Macve, Lucine Nahabedian

Publikováno v: Rheumatology. 57

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2ada66d41bdd4c8e37320872852834a4
https://doi.org/10.1093/rheumatology/key273.032